ArticleReviews in urology2009
The role of immunotherapy in prostate cancer: an overview of current approaches in development.
Article in Reviews in urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- CXCL12-mediated T cell infiltration drives breast cancer metastasis.Clinical and experimental medicine · 2026Article
- Role of Circular RNAs in Prostate Cancer.Current medicinal chemistry · 2024Review
- Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer.Life (Basel, Switzerland) · 2023Review
- Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number.Biology direct · 2022Review
- Targeting the Immune system and Epigenetic Landscape of Urological Tumors.International journal of molecular sciences · 2020Review
- CART cell therapy for prostate cancer: status and promise.OncoTargets and therapy · 2019Review
- Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.Expert review of vaccines · 2015Review
- Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy.Oncogene · 2014Review
- Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Frontiers in immunology · 2014Review
- Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic T lymphocyte function in a mouse mammary model.BioMed research international · 2013Article
- Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Nature reviews. Urology · 2012Review
- Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.Journal of clinical immunology · 2012Review
- Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.P & T : a peer-reviewed journal for formulary management · 2011Article
- Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.Cancer immunology, immunotherapy : CII · 2010Article
- Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.The open prostate cancer journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ongoing clinical trials provide promise for the introduction of immunotherapy into the armamentarium against prostate cancer, but the precise role for immunotherapy remains to be determined. Combinations of immunotherapies may be needed to improve the response rates and the duration of response. Investigators have begun to examine the effect of immunotherapy in combination with other standard treatment, including as an adjuvant to chemotherapy or radiotherapy and as a neoadjuvant agent before prostatectomy. Although many studies examine efficacy in men with metastatic hormone-refractory prostate cancer, there is some evidence for improved responses at earlier stages of disease: the ability of the tumor to evade the immune system may be lessened with lower tumor burden, or the immune system may already be weakened in men with later stages of disease.
Indexed as
Identifiers
19390671PMC2668837W294577903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.